• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[Daily oral low-dose etoposide therapy for aged patients with relapsed aggressive lymphoma].

作者信息

Kura Y, Sawada U, Satoh Y, Irie T, Tsuboi I, Horie T

机构信息

Dept. of Internal Medicine, Nihon University School of Medicine.

出版信息

Gan To Kagaku Ryoho. 1995 Sep;22(10):1393-6.

PMID:7668876
Abstract

Two patients with relapsed Non-Hodgkin's lymphoma (NHL) were treated with oral administration of etoposide. In these patients, long-term hematological remission was obtained. One patient was a 76-year-old man, who was successfully treated with CHOP for diffuse large cell NHL stage III B. One year after obtaining CR, he was admitted to our hospital for enlargement of lymph node. Rebiopsy of lymph node made a diagnosis of relapse from NHL. A new regimen of oral administration of etoposide treatment was employed. Hematological remission was obtained and continued for 3 years. Without interfering with his quality of life. The other patient was a 74-year-old man, who was treated with 6 cycles of CHOP for diffuse large cell NHL stage IV B. The patient attained complete remission following an additional 2 cycles of COMLA therapy. Eight years later, he was admitted for enlargement of lymph node. Rebiopsy of lymph node provided the basis for a diagnosis of relapse from NHL. Oral administration of etoposide treatment was started. Hematological remission was obtained and has been continued until now. These results show that oral administration of etoposide treatment is effective for some patients with recurrent NHL.

摘要

相似文献

1
[Daily oral low-dose etoposide therapy for aged patients with relapsed aggressive lymphoma].
Gan To Kagaku Ryoho. 1995 Sep;22(10):1393-6.
2
Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.复发侵袭性淋巴瘤的治疗:含与不含高剂量治疗及干细胞救援的方案
Cancer Chemother Pharmacol. 2002 May;49 Suppl 1:S13-20. doi: 10.1007/s00280-002-0447-1. Epub 2002 Apr 12.
3
[Successful oral administration of etoposide therapy for refractory malignant lymphoma treated with frequent combination chemotherapy].
Gan To Kagaku Ryoho. 1993 Aug;20(10):1391-5.
4
[Treatment of aggressive non-Hodgkin's lymphoma with the ProMACE- CytaBOM protocol].采用ProMACE-CytaBOM方案治疗侵袭性非霍奇金淋巴瘤
Srp Arh Celok Lek. 1998 Sep-Oct;126(9-10):345-8.
5
Impact of three courses of intensified CHOP prior to high-dose sequential therapy followed by autologous stem-cell transplantation as first-line treatment in poor-risk, aggressive non-hodgkin's lymphoma: comparative analysis of Dutch-Belgian Hemato-Oncology Cooperative Group Studies 27 and 40.在高危侵袭性非霍奇金淋巴瘤一线治疗中,大剂量序贯疗法联合自体干细胞移植前进行三个疗程强化CHOP方案的影响:荷兰-比利时血液肿瘤协作组研究27和40的对比分析
J Clin Oncol. 2005 Jun 1;23(16):3793-801. doi: 10.1200/JCO.2005.07.039. Epub 2005 Apr 4.
6
[Comparing CHOP, CHOP+HD-MTX,and BFM-90 regimens in the survival rate of children and adolescents with B cell non-Hodgkin's lymphoma].[比较CHOP、CHOP+HD-MTX和BFM-90方案对儿童和青少年B细胞非霍奇金淋巴瘤生存率的影响]
Ai Zheng. 2004 Aug;23(8):933-8.
7
[Chemotherapy for two patients with non-Hodgkin's lymphoma in hemodialysis].[两名血液透析的非霍奇金淋巴瘤患者的化疗]
Rinsho Ketsueki. 1996 Aug;37(8):688-93.
8
[Clinical analysis of 282 patients with non-Hodgkin's lymphoma].282例非霍奇金淋巴瘤患者的临床分析
Hunan Yi Ke Da Xue Xue Bao. 2003 Jun;28(3):237-9.
9
Combined chemotherapy with carmustine, doxorubicin, etoposide, vincristine, and cyclophosphamide plus mitoxantrone, cytarabine and methotrexate with citrovorum factor for the treatment of aggressive non-Hodgkin lymphoma: a long-term follow-up study.卡莫司汀、多柔比星、依托泊苷、长春新碱和环磷酰胺联合米托蒽醌、阿糖胞苷及甲氨蝶呤加亚叶酸钙治疗侵袭性非霍奇金淋巴瘤的长期随访研究
Cancer. 2005 Mar 1;103(5):970-7. doi: 10.1002/cncr.20891.
10
A variant of ProMACE-CytaBOM chemotherapy for non-Hodgkin's lymphoma with threefold higher drug dose size but identical cumulative dose intensity. A pilot study of the Italian lymphoma study group (GISL).一种用于非霍奇金淋巴瘤的ProMACE-CytaBOM化疗方案变体,药物剂量大小提高了三倍,但累积剂量强度相同。意大利淋巴瘤研究组(GISL)的一项试点研究。
Haematologica. 2000 Mar;85(3):263-8.